A peripheral vasopressor can be a bridge—not a synonym for unsafe care or a guarantee of safety. In a shock MCQ, once you consider whether a peripheral route can permit timely treatment, ask the more discriminating question: what makes this particular peripheral infusion monitorable, and what would make you change course?
A sparse stem may tell you only that the patient is hypotensive and peripheral access is difficult. It may not specify the shock mechanism, vein, infusion concentration, or expected duration. Don’t invent those details, and don’t choose a pressor solely from an access problem: shock physiology still matters.
For adults with septic shock, the 2026 Surviving Sepsis Campaign suggests starting vasopressors peripherally rather than delaying for central access. The recommendation is conditional and based on very-low-certainty evidence; the guideline says evidence is insufficient to set a universal duration, dose, IV size, or insertion site. That is not a blanket rule for every type of shock or every patient.
Turn “peripheral access” into a safety plan
When answer choices differ in how they handle the infusion, look for a plan that covers three things: a usable site, active monitoring, and a way to escalate. A bare statement that peripheral pressors are acceptable is less complete than one that explains how the team will detect a problem and respond.
| Checkpoint | What a strong answer makes clear | Reasoning trap to avoid |
|---|---|---|
| The site | The IV is secure, patent, accessible for inspection, and suitable under local policy. | Treating any working IV as suitable for an infusion that may continue. |
| The infusion | Staff use the approved medication concentration and delivery setup, and reassess blood pressure and perfusion. | Assuming that the line’s initial appearance guarantees ongoing patency. |
| The next step | The team will reassess the need for the infusion and arrange more durable access if the situation requires it. | Memorizing one dose, site, or time limit as universal. |
In the ED, a line can become hard to inspect under blankets, during transport, or when the patient cannot report discomfort. Keep the site visible when possible, confirm patency according to local process, and make sure the team knows who is checking it. The choice of vein, catheter size, medication concentration, and monitoring interval should follow the institution’s protocol—not a number recalled without its context.
Recognize when the bridge is no longer adequate
New pain or burning, swelling, blanching, coolness, leakage, or a concerning change in the site should prompt immediate reassessment for infiltration or extravasation. A normal-looking site at one check is not proof that the infusion remains intravascular later.
If extravasation is suspected, stop the infusion through that catheter and leave it in place initially; do not flush it. Promptly secure verified alternative access so necessary vasoactive support can continue, and activate the local extravasation pathway. That pathway commonly calls for aspirating residual medication through the original catheter before removal; antidote and further measures should follow the local protocol.
A continuing or escalating vasopressor requirement, need for multiple infusions, or a site that cannot be reliably monitored should prompt a deliberate access and monitoring plan. Those are reasons to reassess—not universal numerical cutoffs. Central access may be appropriate when ongoing treatment requires it, but the initial peripheral bridge does not itself prove that a central line must be placed.
Evidence helps explain why the answer needs both reassurance and caution. In one prospective study of 150 adults in a single emergency department, extravasation occurred in three patients, with no significant morbidity reported under close observation. Most participants had septic shock. This is useful context, not proof of zero risk or a universal safety rate: the study was conducted at one center using its own protocol.
Avoid these MCQ reasoning errors
- Making the line the whole problem. Access is one part of resuscitation; the shock mechanism and the need for vasoactive support still require assessment.
- Turning local practice into an exam law. The current sepsis guideline does not establish one universally safe peripheral dose, site, catheter size, or duration.
- Confusing “can start peripherally” with “can continue peripherally indefinitely.” Starting a bridge and deciding whether it remains appropriate are separate judgments.
- Treating “no visible extravasation yet” as “no risk.” Continued observation is part of the safety plan.
A four-minute retrieval exercise
Close your notes. Give yourself 90 seconds to answer this altered stem: an adult remains hypotensive, the cause is not yet established, and central access will take time. A working peripheral IV is available, but the stem gives no exact site or infusion duration.
Write four short lines: (1) what you can decide about access without pretending to know the shock type; (2) how you will make the line and infusion monitorable under local policy; (3) which site changes would make you suspect extravasation and what you would do first; and (4) what change in the patient’s ongoing support needs should trigger an access reassessment.
Then check your answer against those four tasks. If you wrote a universal gauge, dose, or time limit, ask whether the stem or the guideline actually supplied it. Retrieval practice is useful here because it makes you recall the limits of the rule—not just the phrase “peripheral pressors are acceptable.”
Practical takeaways
- In adult septic shock, current guidance supports starting vasopressors peripherally rather than delaying solely for central access; do not automatically generalize that recommendation to every shock state.
- A defensible peripheral bridge includes an inspectable, functioning site, protocol-based infusion setup, and ongoing reassessment.
- Pain, swelling, blanching, coolness, or leakage at the site calls for immediate action: stop the infusion through that catheter, use another verified route, and follow the local extravasation pathway.
- Do not claim a universal peripheral dose, IV size, insertion site, or duration when current evidence does not establish one.
